Search

Next generation immuno-oncological targets for cancer therapy

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2025-10-29

Subtype-dependent biomarkers for systemic therapy in bladder cancer

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2025-10-29

Contact

Address Medicon Village - Building 406Sheelevägen 2 223 81 LundSweden Are you applying for a position? For general questions regarding the call, contact us at:canfaster-postdoc [at] immun [dot] lth [dot] se (canfaster-postdoc[at]immun[dot]lth[dot]se) DirectorSara Ek, Professorsara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se)+46-46-222-3824 Research coordinatorJana H

https://www.createhealth.lth.se/canfaster/contact - 2025-10-29

Contact

Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden

https://www.createhealth.lth.se/contact - 2025-10-29

About

Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solutions, which can be implemented into the clinic with much shorter lead times. CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and pr

https://www.createhealth.lth.se/about - 2025-10-29

News

Promising results for Lead Biologics’ first-in-class checkpoint inhibitor published in Nature Cancer Lead Biologics takes a major step towards a new cancer treatment. A new study shows that the company’s drug candidate effectively inhibits a previously unknown immune escape mechanism and eliminates acute myeloid leukemia cells in advanced experimental models.– This confirms the great interest in

https://www.createhealth.lth.se/news-0 - 2025-10-29

Research and Innovation

Focus AreasPsychological Resilience in Cancer, Bioinformatics and AIOngoing Collaborations and partnersCantargia, IMMUNOVIA, Paindrainer, Akuru PharmaSpin OutsWorking together is an integral part of CREATE Health’s DNA

https://www.createhealth.lth.se/research-and-innovation - 2025-10-29

Focus Areas

CREATE Health has been a leader in developing novel therapeutic and diagnostic innovations, which have been further developed in a commercial setting in a start-up company. Immuno-OncologyImmuno-oncology has provided a number of very exciting clinical improvements, by focussing on how the immune system regulates tumor eradication. This has been achieved by the discovery and functional implementati

https://www.createhealth.lth.se/research-and-innovation/focus-areas - 2025-10-29

Funding

In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are distributed over a five-year period and dedicated to translational cancer research within the L2CancerBridge program.Other previous and current funding for the CREA

https://www.createhealth.lth.se/about/funding - 2025-10-29

Search results

Filter

Your search for "*" yielded 128061 hits

Next generation immuno-oncological targets for cancer therapy

Subtype-dependent biomarkers for systemic therapy in bladder cancer

Contact

Contact

About

News

Research and Innovation

Focus Areas

Funding

E:1124

E:1328

E:1406

E:1407

E:1426

E-1517a

E:LÄSALÄSA

E:TYSTATYSTA

Våning 2

E:2113c

E:2116

Use of cookies

Search results

Filter

Your search for "*" yielded 128061 hits